Unknown

Dataset Information

0

Analyzing mRNAsi-Related Genes Identifies Novel Prognostic Markers and Potential Drug Combination for Patients with Basal Breast Cancer.


ABSTRACT: Basal breast cancer subtype is the worst prognosis subtypes among all breast cancer subtypes. Recently, a new tumor stemness index-mRNAsi is found to be able to measure the degree of oncogenic differentiation of tissues. The mRNAsi involved in a variety of cancer processes is derived from the innovative application of one-class logistic regression (OCLR) machine learning algorithm to the whole genome expression of various stem cells and tumor cells. However, it is largely unknown about mRNAsi in basal breast cancer. Here, we find that basal breast cancer carries the highest mRNAsi among all four subtypes of breast cancer, especially 385 mRNAsi-related genes are positively related to the high mRNAsi value in basal breast cancer. This high mRNAsi is also closely related to active cell cycle, DNA replication, and metabolic reprogramming in basal breast cancer. Intriguingly, in the 385 genes, TRIM59, SEPT3, RAD51AP1, and EXO1 can act as independent protective prognostic factors, but CTSF and ABHD4B can serve as independent bad prognostic factors in patients with basal breast cancer. Remarkably, we establish a robust prognostic model containing the 6 mRNAsi-related genes that can effectively predict the survival rate of patients with the basal breast cancer subtype. Finally, the drug sensitivity analysis reveals that some drug combinations may be effectively against basal breast cancer via targeting the mRNAsi-related genes. Taken together, our study not only identifies novel prognostic biomarkers for basal breast cancers but also provides the drug sensitivity data by establishing an mRNAsi-related prognostic model.

SUBMITTER: Huang K 

PROVIDER: S-EPMC8505092 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature

altmetric image

Publications

Analyzing mRNAsi-Related Genes Identifies Novel Prognostic Markers and Potential Drug Combination for Patients with Basal Breast Cancer.

Huang Kai K   Wu Yu Y   Xie YunQing Y   Huang LiYing L   Liu Hong H   Liu Hong H  

Disease markers 20211004


Basal breast cancer subtype is the worst prognosis subtypes among all breast cancer subtypes. Recently, a new tumor stemness index-mRNAsi is found to be able to measure the degree of oncogenic differentiation of tissues. The mRNAsi involved in a variety of cancer processes is derived from the innovative application of one-class logistic regression (OCLR) machine learning algorithm to the whole genome expression of various stem cells and tumor cells. However, it is largely unknown about mRNAsi in  ...[more]

Similar Datasets

| S-EPMC9578885 | biostudies-literature
| S-ECPF-GEOD-21653 | biostudies-other
2013-07-02 | PXD000309 | Pride
2010-05-05 | E-GEOD-21653 | biostudies-arrayexpress
2010-05-05 | GSE21653 | GEO
| S-EPMC7106759 | biostudies-literature
| S-EPMC9027215 | biostudies-literature
| S-EPMC10855431 | biostudies-literature
| S-EPMC3999971 | biostudies-literature
| S-EPMC5582957 | biostudies-literature